Reduce movement problems with supplement
- Trial ID
- NCT07064005
- Official Title
- Brain Glutathione (GSH) Enrichment Through Gamma-glutamylcysteine (GGC) Supplementation in Early Parkinson's Disease Patients for Reduction of Extrapyramidal Motor Disturbances and Halting Cognition Decline: A Pilot Trial
- Goal
- Reduce movement problems with supplement
- Phase
- PHASE1
- Status
- RECRUITING
- Sponsor
- Pravat Mandal
- Study Type
- INTERVENTIONAL
- Enrollment
- 12 participants
- Conditions
- Parkinsons Disease (PD)
- Interventions
- Gamma- glutamylcysteine
Plain-Language Summary
The goal is to see whether boosting brain glutathione can reduce Parkinson's extrapyramidal movement problems and help prevent early thinking decline. In a Phase 1 pilot, participants take gamma-glutamylcysteine, the direct building block the body uses to make glutathione, with the idea that higher antioxidant levels in the brain will protect dopamine neurons from oxidative damage; it is intended as an add-on not a replacement for levodopa, and no specific interactions with levodopa are expected. The trial will enroll 12 people aged 50 to 80 with confirmed Parkinson's and normal cognition on the MoCA (score ≥ 26), who can read and write English. People with metal implants or claustrophobia, dementia, active psychosis, recent serious liver or kidney disease, current antioxidant supplements, recent head injury, cancer, or substance abuse are excluded.
Locations
- UPMC Presbyterian Hospital, Pittsburgh, Pennsylvania, United States
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Gamma- glutamylcysteine. The goal is to see whether boosting brain glutathione can reduce Parkinson's extrapyramidal movement problems and help prevent early thinking decline. In a Phase 1 pilot, participants take gamma-glutamylcysteine, the direct building block the body uses to make glutathione, with the idea that higher antioxidant levels in the brain will protect dopamine neurons from oxidative damage; it is intended as an add-on not a replacement for levodopa, and no specific interactions with levodopa are expected. The trial will enroll 12 people aged 50 to 80 with confirmed Parkinson's and normal cognition on the MoCA (score ≥ 26), who can read and write English. People with metal implants or claustrophobia, dementia, active psychosis, recent serious liver or kidney disease, current antioxidant supplements, recent head injury, cancer, or substance abuse are excluded.
- Who can participate?
- Participants must be between 50 Years and 80 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This Phase 1 trial is estimated to last approximately 1 year and 5 months.